样式: 排序: IF: - GO 导出 标记为已读
-
Appraisal of a newly developed ALBI-sarcopenia score as a prognostic marker in patients with hepatocellular carcinoma. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-04-17 Maha Elsabaawy, Hanaa Badran, Amr Ragab, Rasha Abdelwahab, Eman Sayed, Sameh Afify, Warda Othman
This study aimed to evaluate the impact of the combined Albumin-bilirubin (ALBI)/sarcopenia score as a newly developed prognostic model for hepatocellular carcinoma (HCC), with a focus on its utility in predicting mortality.
-
Improvement of quality of care provided to outpatients with hepatic cirrhosis after an educational intervention. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-04-15 Alberto Amador, Silvia Salord, Xavier Xiol, Marta Garcia-Guix, Alba Cachero, Rosa Rota, Nerea Hernandez Aretxabaleta, Carme Baliellas, Jose Castellote
A set of indicators has been reported to measure the quality of care for cirrhotic patients, and previously published studies report variable adherence rates to these indicators. This study aimed to assess the quality of care provided to cirrhotic outpatients before and after an educational intervention by determining its impact on adherence to quality indicators.
-
Causal effect between gut microbiota and gastroesophageal reflux disease: a bidirectional two-sample Mendelian randomization study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-04-15 Jingyu Liu, Tongxin Zhang, Xiao Liu, Qian Wang, Huawei Zhang
Previous observational studies have found that the gut microbiota is closely related to the pathogenesis of gastroesophageal reflux disease (GERD), while their causal relationship is unclear. A two-sample multivariate Mendelian randomization analysis was implemented to estimate the causal effect of gut microbiota on GERD. The gut microbiota aggregated statistics were derived from a meta-analysis of
-
Long-term outcomes of intestinal penetrating Crohn's disease following successful nonoperative management. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-04-05 Zhenya Sun, Lei Cao, Yusheng Chen, Weiming Zhu, Yi Li
There is a paucity of data on the surgical or medical treatment for abscess/fistula complicating Crohn's disease after successful nonsurgical management. We conducted a cohort study to investigate the long-term outcomes and the risk factors for the requirement of subsequent surgical intervention in Crohn's disease patients with complicating fistulas/abscess following successful nonsurgical management
-
The effect of implementing a transanal minimally invasive surgical programme for the local excision of early rectal neoplasia on outcomes in a tertiary referral rectal cancer centre. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-04-05 William P Duggan, John Lenihan, Cillian Clancy, Deborah A McNamara, John P Burke
Transanal minimally invasive surgery (TAMIS) is a surgical alternative to proctectomy in the management of complex rectal polyps and early rectal cancers. In 2016, our institution introduced a TAMIS programme. The purpose of this study was to evaluate changes in practice and outcomes in our institution in the 3 years before and after the implementation of TAMIS. We conducted a retrospective analysis
-
Antidepressant treatment in inflammatory bowel disease: a systematic review and meta-analysis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-04-05 Frances Weston, Ben Carter, Nick Powell, Allan H Young, Calum D Moulton
Around 25% of patients with inflammatory bowel disease (IBD) have depressive symptoms, yet antidepressants have been poorly studied in IBD. We systematically searched IBD studies testing antidepressants in four databases. Outcomes were depressive symptoms, anxiety, IBD disease activity, quality of life (QoL) and adverse events. For randomized controlled trials (RCTs), we performed random-effects meta-analysis
-
Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care? Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-04-02 Katja Tepeš, Jurij Hanžel, David Štubljar, Karin Strmšek, Luka Erjavec, Eva Supovec, Zala Jagodic, Mirjam Končan, Jan Grosek, Jurij Aleš Košir, Aleš Tomažič, Urška Kogovšek, Gregor Norčič, Renata Šibli, Marija Žnidaršič, Tadeja Pačnik Vižintin, Barbara Sodin, Janez Breznik, Vanesa Anderle Hribar, Andreja Ocepek, Cvetka Pernat Drobež, Nejc Bukovnik, Andrej Zafošnik, Tamara Marušič, Nataša Jurečič Brglez
With the increasing number of inflammatory bowel disease (IBD) patients, it is difficult to manage them within specialised IBD teams in academic medical centres: many are therefore treated in nonacademic IBD centres. It is unclear whether the time to introducing biologics is the same in both settings.
-
Histopathological staging and differential diagnosis of marginal zone lymphoma of gastric mucosa-associated lymphoid tissue. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-04-02 Dong-Feng Ge, Yang-Kun Wang, Shen-Lin Li, Xiong-Fei Zou, Ling-Chao Kong, Wei-Yi Deng, Su-Nan Wang
The purpose of this study was to explore the histopathological staging and differential diagnosis of marginal zone lymphoma in gastric mucosa-associated lymphoid tissue (MALT lymphoma). We performed detailed histomorphology and immunohistochemistry investigations as well as genetic testing on endoscopic biopsy and endoscopic mucosal resection specimens from 18 patients with gastric MALT lymphoma. We
-
Long-term outcomes of patients with autoimmune hepatitis induced cirrhosis after immunosuppressive treatment. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-28 Sara Hatoum, Don C Rockey
Autoimmune hepatitis is an immune-mediated liver disease that results in hepatic inflammation and subsequent fibrosis. We aimed to assess the natural history of autoimmune hepatitis in patients who had cirrhosis at the time of diagnosis.
-
Efficacy of radiofrequency ablation vs. transcatheter arterial embolization for hepatic hemangiomas. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-28 Jushang Li, Shuaiguo Zhang, Chunmin Ning, Guoming Li, Shigang Guo
The objective of this study was to evaluate the safety and effectiveness of radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) in the treatment of large hepatic hemangiomas (LHH) (5-9.9 cm in diameter).
-
Diagnostic value of balloon expulsion test and anorectal manometry in patients with constipation: a systematic review and meta-analysis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-25 Dan Xu, Mengfei Kuang, Ya Liu, Hua Jiang
This study aims to compare the diagnostic value of balloon expulsion test and anorectal manometry in patients with constipation through meta-analysis. Databases, encompassing PubMed, EMBASE, Cochrane Library, Web of Science, etc. were searched for all English publications on the diagnosis of constipation using balloon expulsion test and anorectal manometry. The publication date was restricted from
-
A new and simple score to predict adequate and deep response to ursodeoxycholic acid in patients with primary biliary cholangitis: the ALP-A score. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-25 Guilherme Grossi Lopes Cançado, Nathalia Mota de Faria Gomes, Cláudia Alves Couto, Eduardo Luiz Rachid Cançado, Debora Raquel Benedita Terrabuio, Cristiane Alves Villela-Nogueira, Michelle Harriz Braga, Mateus Jorge Nardelli, Luciana Costa Faria, Elze Maria Gomes Oliveira, Vivian Rotman, Maria Beatriz Oliveira, Simone Muniz Carvalho Fernandes da Cunha, Daniel Ferraz de Campos Mazo, Liliana Sampaio
Ursodeoxycholic acid (UDCA) is the standard treatment for primary biliary cholangitis (PBC), but a significant proportion of patients do not respond adequately, leading to increased risk of adverse outcomes. This study aims to develop a new and straightforward predictive score to identify PBC patients likely to achieve a complete response to UDCA.
-
Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: the influence of alcohol consumption. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-22 Motoh Iwasa, Ryosuke Sugimoto, Akiko Eguchi, Yasuyuki Tamai, Ryuta Shigefuku, Naoto Fujiwara, Hideaki Tanaka, Yoshinao Kobayashi, Jiro Ikoma, Masahiko Kaito, Hayato Nakagawa
Pemafibrate is a selective peroxisome proliferator-activated receptor α modulator that improves serum alanine aminotransferase (ALT) in dyslipidemia patients. We previously reported that pemafibrate significantly improves liver function, serum triglyceride (TG) levels and liver stiffness in non-alcoholic fatty liver disease patients, however the influence of alcohol consumption was not considered.
-
Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-22 Tarun Chhibba, Emily C L Wong, Walter Reinisch, Laura Targownik, Neeraj Narula
Vedolizumab is a first-line treatment option for ulcerative colitis. There are differences in incidence of ulcerative colitis between males and females, but whether sex affects treatment outcomes is less clear. We examined sex-based differences in patients with ulcerative colitis initiated on vedolizumab from two major randomized controlled trials (RCTs). We conducted a post-hoc analysis on participants
-
Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-22 Weijing Zhang, Wen Jing Song, Weiyu Chen, Zoucheng Pan, Jiawei Zhang, Li Fan, Jie Li
Metabolic dysfunction-associated steatotic liver disease (MASLD) (previously called nonalcoholic fatty liver disease, NAFLD) is associated with cardiometabolic risk factors and chronic kidney disease (CKD). However, evidence is lacking regarding whether the severity of fibrosis is affected by these risk factors and diseases and to what degree. We aimed to determine the correlation between these factors
-
Vonoprazan-amoxicillin dual therapy with different amoxicillin dosages for treatment-naive patients of Helicobacter pylori infection in China: a prospective, randomized controlled study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-19 Zhu Liu, Dongjie Sun, Luan Kou, Li Jia, Jiaorong Hao, Jihai Zhou, Wenwen Zheng, Fengyu Gao, Xin Chen
The vonoprazan (VPZ)-amoxicillin (AMO) dual therapy (VA) demonstrates a satisfactory eradication rate for Helicobacter pylori (H. pylori). However, the optimal dosage of AMO in this regimen remains uncertain. The objective of this study is to investigate the efficacy of different doses of AMO in the VA regimen for first-line treatment of H. pylori infection.
-
Association of left ventricular diastolic dysfunction with inflammatory activity, renal dysfunction, and liver-related mortality in patients with cirrhosis and ascites. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-19 Georgios Kalambokis, Maria Christaki, Ilias Tsiakas, Grigorios Despotis, Lampros Lakkas, Spiridon Tsiouris, Xanthi Xourgia, Georgios S Markopoulos, Lefkothea Dova, Haralampos Milionis
Left ventricular diastolic dysfunction (LVDD) is the predominant cardiac abnormality in cirrhosis. We investigated the association of LVDD with systemic inflammation and its impact on renal function, occurrence of hepatorenal syndrome (HRS) and survival in patients with cirrhosis and ascites. We prospectively enrolled 215 patients with cirrhosis and ascites. We evaluated the diagnosis and grading of
-
A comparative study of three ultrasound techniques for liver fibrosis staging. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-19 Qianqian Shen, Jiaqi Zhang, Shangjie Yang, Liping Liu
The aim of this study is to assess the agreement and performance of visual transient elastography (ViTE), sound touch elastography (STE), and sound touch quantification (STQ) for liver fibrosis staging using transient elastography (TE) as a standard. We finally enrolled 252 subjects with chronic liver disease (CLD) who underwent ViTE, STE, STQ, and TE examinations simultaneously in our hospital from
-
Savings in social expenditures for work incapacity in patients with inflammatory bowel disease depend on access to innovative therapies in Poland. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-19 Edyta Zagórowicz, Grzegorz Binowski, Dominik Strządała, Cezary Pruszko, Piotr Kucha, Jarosław Reguła
Inflammatory bowel diseases (IBD) are an increasing burden for societies. We examined Polish Social Insurance Institution (ZUS) work incapacity expenditures for people with IBD compared with the general population.
-
Association of Helicobacter pylori CagA seropositivity with gastric precancerous lesions: a systematic review and meta-analysis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-19 Zengyun Qiao, Enbo Wang, Boyang Bao, Xiaodong Tan, Liu Yuan, Dong Wang
The objective of this meta-analysis is to delineate the association between H. pylori CagA serological status and the prevalence of gastric precancerous lesions (GPL). We searched peer-reviewed articles up to October 2023. The extraction of data from the included studies was carried out as well as the quality assessment. Pooled effect sizes were calculated using a random effect model. Thirteen studies
-
Paraneoplastic gastrointestinal dysmotility due to non-Hodgkin diffuse large B cell lymphoma: a case report. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-12 Emily Nash, John D Chetwood, Aravind G Tamilarasan, Emilia Prakoso
Paraneoplastic gastrointestinal dysmotility is a rare entity which occurs in association with malignancy. We present the second case associated with lymphoma, characterised by generalised gastrointestinal dysmotility with constipation, malnutrition, weight loss, and capsule endoscope retention. This case highlights the importance of maintaining a high index of suspicion for malignancy in patients with
-
Fatigue, depression, and sleep disorders are more prevalent in patients with metabolic-associated fatty liver diseases. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-12 Alaa M Mostafa, Shaimaa Moustafa Hafez, Noha M Abdullah, Yasser Fouad
To determine the prevalence and risk factors for depression, sleep disturbances, and exhaustion in MAFLD patients.
-
Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-12 Theodore Rokkas, Javier P Gisbert, Konstantinos Ekmektzoglou, Themistocles Dassopoulos, Yaron Niv, Colm O'Morain
Βiologic agents and small molecules have expanded the therapeutic armamentarium of moderate to severe ulcerative colitis (UC). However, their comparative efficacy and safety performance as maintenance treatments have not been sufficiently explored. We performed a systematic review and network meta-analysis (NWM) to assess the comparative efficacy and safety of all approved and emerging treatments for
-
Clinical outcomes with metformin use in diabetic patients with compensated cirrhosis: a systematic review and meta-analysis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-11 Spyros Peppas, Stavros Doumas, Advait Suvarnakar, Jiling Chou, Ayah Arafat, Akram I Ahmad, James H Lewis
Previous studies have demonstrated a beneficial effect of metformin in patients with cirrhosis, but no improvement in liver histology.
-
High antibiotic resistance rates in Helicobacter pylori strains in Turkey over 20 years: implications for gastric disease treatment. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-11 Burak Sarikaya, Riza Aytaç Çetinkaya, Derya Özyiğitoğlu, Sinem Akkaya Işik, Mustafa Kaplan, Duygu Kirkik, Levent Görenek
Helicobacter pylori (Hp) eradication therapy is crucial for preventing the development of gastritis, peptic ulcers, and gastric cancer. An increase in resistance against antibiotics used in the eradication of Hp is remarkable. This meta-analysis aims to examine the resistance rates of Hp strains isolated in Turkey over the last 20 years against clarithromycin (CLR), metronidazole (MTZ), levofloxacin
-
Sugar-sweetened beverage intake and long-term mortality in individuals with metabolic dysfunction-associated steatotic liver disease: a longitudinal analysis of the National Health and Nutrition Examination Survey database. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-11 Ji Zhou, Chu Liu, Lili Liu, Lei Li
Consuming sugar-sweetened beverages (SSBs) has been linked to the development of various adverse health conditions, including metabolic dysfunction-associated steatotic liver disease (MASLD). This study evaluated associations between SSB intake and long-term mortality among individuals with MASLD using a nationally representative database.
-
Idiopathic chronic intestinal pseudo-obstruction syndrome is strongly associated with low serum levels of vitamin D. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-11 Alba Panarese, Elton Dajti, Leonardo Henry Eusebi, Amanda Vestito, Rocco Maurizio Zagari
Idiopathic chronic intestinal pseudo-obstruction (CIPO) is associated with intestinal inflammation and malabsorption and may cause serum vitamin D deficiency. We aimed to assess whether there is an association between idiopathic CIPO and serum levels of 25-hydroxy-vitamin D. Consecutive patients with confirmed diagnosis of idiopathic CIPO were prospectively enrolled and matched with healthy controls
-
Prevalence, trends, and characteristics of metabolic dysfunction-associated steatotic liver disease among the US population aged 12-79 years. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-11 Tsung-Hua Shen, Chung-Hsuen Wu, Yuan-Wen Lee, Chun-Chao Chang
Clinical observation revealed an increase in metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence among adults and adolescents and young adults (AYA). However, its prevalence trend in specific subgroups and its characteristics are unclear.
-
The influence of carvedilol posology timing on clinically significant portal hypertension: insights from elastography measurements. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-11 Bruno Besteiro, Manuel Marques da Cruz, Cláudia Alves, Fátima Costa, Mariana Nunes, Daniel Martinho Dias, Ana Barreira, Joana Calvão, Mónica Mesquita, Sónia Carvalho, Inês Pinho, Paulo Carrola, José Presa Ramos
Carvedilol has emerged as the preferred β-blocker for treating portal hypertension. However, there is still a debate in dosing regimen, with a potential lower bioavailability in once-daily regimens. The aim of this study is to assess the acute effects of carvedilol posology in patients with clinically significant portal hypertension (CSPH), as a surrogate marker of bioavailability.
-
Prognostic analysis of sex and age in hepatocellular carcinoma: a SEER study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-04 Jun Chen, Xiao Wang, Wenyi Ye
This study aimed to explore the impact of sex on clinical features and survival among hepatocellular carcinoma (HCC) patients.
-
The frequency and clinical significance of antibodies to soluble liver antigen/liver pancreas in autoimmune hepatitis: a prospective single-center study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-04 Osman Yüksekyayla, Nabi Kina, Arjen Ulaba, Mehmet Emin Ergün, Ersin Batibay, Cem Şimşek, Fadile Yildiz Zeyrek, Staffan Wahlin, Cumali Efe
Soluble liver antigen/liver pancreas antibodies (anti-SLA/LP) are specific markers for autoimmune hepatitis (AIH) that have been associated with a distinct clinical phenotype and a more aggressive form of AIH. We prospectively evaluated the frequency and clinical significance of anti-SLA/LP in Turkish patients with AIH.
-
Efficacy and safety of naldemedine for opioid-induced constipation in older patients with cancer: a retrospective study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-04 Hisao Imai, Yukiyoshi Fujita, Eriko Hiruta, Takashi Masuno, Shigeki Yamazaki, Hajime Tanaka, Teruhiko Kamiya, Mitsuru Sandoh, Satoshi Takei, Kazuya Arai, Hiromi Nishiba, Junnosuke Mogi, Shiro Koizuka, Taeko Saito, Kyoko Obayashi, Kyoichi Kaira, Koichi Minato
Opioids are pain relievers that are often associated with opioid-induced constipation (OIC) that worsens with age. We performed a multicenter, retrospective analysis on the efficacy and safety of naldemedine, an opioid receptor antagonist, in treating OIC in patients with cancer (age >75 years).
-
Time trends in liver cancer mortality rates in Montenegro from 1990 to 2018. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-04 Mirjana Nedović Vuković, Marina Jakšić, Danijela Stojanović, Brigita Smolović
Liver cancer is the third most common cause of cancer-related deaths worldwide. Hepatitis B and C infections are the main factors affecting mortality. During recent years, Montenegro conducted activities on eradication of viral hepatitis according to the global strategy for the primary prevention of liver cancer mortality. The objective of this study was to assess the liver cancer mortality trend in
-
Referral for liver transplant following acute variceal bleeding: a multicenter cohort study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-04 Sofia Bragança, Marta Ramos, Sara Lopes, Gonçalo Alexandrino, Milena Mendes, Rui Perdigoto, João Coimbra, Hugo P Marques, Filipe S Cardoso
Referral for liver transplant (LT) following acute variceal bleeding (AVB) varies widely. We aimed to characterize and assess its impact on clinical outcomes.
-
Iron therapy supplementation in inflammatory bowel disease patients with iron deficiency anemia: findings from a real-world analysis in Italy. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-03-01 Gionata Fiorino, Jean-Frederic Colombel, Kostas Katsanos, Fermín Mearin, Jürgen Stein, Margherita Andretta, Stefania Antonacci, Loredana Arenare, Rita Citraro, Stefania Dell'Orco, Luca Degli Esposti, Antonio Ramirez de Arellano Serna, Neige Teldja Morin, Ioannis E Koutroubakis
This real-world analysis evaluated iron therapy supplementation in inflammatory bowel disease patients with iron-deficiency anemia, considering disease progression and healthcare resource consumption.
-
Magnetic resonance imaging-based rim enhancement could effectually predict poor prognosis in hepatocellular carcinoma: a meta-analysis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-29 Yumin Lu, Yongyi Cen, Xin He, Xiaping Mo, Fang Luo, Yubao Zhong
Recent studies have initially shown that MRI-based rim enhancement associates with poor prognosis in hepatocellular carcinoma (HCC) patients, but their sample sizes are small, leading to a necessary of comprehensive analyses to make a relatively solid statement. Thus, this meta-analysis aimed to summarize the correlation between MRI-based rim enhancement and prognosis in HCC patients. Until March 2023
-
Myosteatosis is an independent risk factor for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunting. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-29 Wenfeng Shi, Hua Yin, Zhijian Yu, Yong Li, Xiao Bai, Sirui Fu, Chongyang Duan, Weiguo Xu, Yang Yang
The relationship between skeletal muscle and adipose tissue compositions and risk of overt hepatic encephalopathy (OHE) following transjugular intrahepatic portosystemic shunt (TIPS) treatment needs to be investigated.
-
Diverticulosis morphology is associated with risk of diverticulitis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-28 Miriam J Levy, Rebecca L Osterkamp, Kristof Glauninger, Lisa L Strate
The size, number and distribution of diverticula vary greatly in patients with diverticulosis. We aimed to study the association between the morphology of diverticulosis assessed on colonoscopy and the risk of diverticulitis. We performed a retrospective, case-control study of cases with a history of diverticulitis and controls with diverticulosis without diverticulitis matched on sex, age (within
-
Second-look upper endoscopy as the initial approach to subepithelial lesions: a reassuring and reliable strategy. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-28 Tiago Lima Capela, Vítor Macedo Silva, Marta Freitas, Tiago Cúrdia Gonçalves, Francisca Dias de Castro, Joana Magalhães, Sílvia Leite, José Cotter
Although endoscopic ultrasound (EUS) plays a critical role in the management of subepithelial lesions (SEL) of upper gastrointestinal tract many can be classified solely by a thorough upper gastrointestinal endoscopy (UGE) which can reduce the burden of additional studies.
-
Association between fecal short-chain fatty acid levels and constipation severity in subjects with slow transit constipation. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-28 Qi Chen, Die Chen, Xiangyue Gao, Ya Jiang, Ting Yu, Liuqin Jiang, Yurong Tang
We measured the fecal levels of short-chain fatty acids (SCFAs) in subjects with slow transit constipation (STC) and assessed the correlation between SCFA levels and disease severity as well as quality of life.
-
Prediction and evaluation of a nomogram model for recurrent acute pancreatitis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-26 Yuan Chen, Shu Huang, Bei Luo, Jiao Jiang, Wensen Ren, Kang Zou, Xiaolin Zhong, Muhan Lü, Xiaowei Tang
The purpose of this study was to investigate the influencing factors for recurrent acute pancreatitis and construct the nomogram model to predict the risk of recurrent acute pancreatitis.
-
Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet's disease. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-23 Hye Kyung Hyun, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
Behçet's disease (BD) and nonalcoholic fatty liver disease (NAFLD) are chronic inflammatory diseases that share pathogenetic mechanisms. In this study, we investigated whether NAFLD influences the clinical outcomes in patients with intestinal BD.
-
Optimizing surveillance of low-risk metabolic dysfunction associated steatotic liver disease using transient elastography. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-23 Harish Gopalakrishna, Gayatri B Nair, Roham Salman Roghani, Natarajan Ravendhran, Yaron Rotman
Most people with metabolic dysfunction-associated steatotic liver disease (MASLD) lack significant fibrosis and are considered low-risk. Surveillance strategy for low-risk MASLD remains uncertain.
-
Evaluation of chronic hepatitis B patients who voluntarily discontinued oral antiviral therapy: is there an answer to the controversial topic? Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-23 Eyüp Arslan, Yeşim Yildiz, Ömer Karaşahin, Yakup Demir, Çiğdem Tümbül Mermutluoğlu, Gülten Ünlü, Ferit Kuşçu, Şafak Kaya, Fethiye Akgül, Tuba Damar Çakirca, Fatma Yilmaz Karadağ, Sibel Altunişik Toplu, Selçuk Nazik, İrem Akdemir, Şafak Özer Balin, Fatma Özlem Kandemir, Dilara İnan, Yaşar Bayindir, Yeşim Taşova, Mustafa Kemal Çelen
The uncertain treatment duration for nucleos(t)ide analogues (NA) used in the treatment of chronic hepatitis B (CHB) is an important problem for both patients and physicians. The aim of this study was to evaluate the determinants of virologic relapse (VR) and the optimum time of treatment discontinuation in the follow-up of CHB patients who voluntarily discontinued treatment after virological suppression
-
Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-23 Yusuke Johira, Takashi Nakahara, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Shiro Oka
This study aimed to clarify the population in whom the presence of metabolic dysfunction-associated fatty liver disease (MAFLD) especially contributes to recurrence after liver resection for non-B, non-C hepatocellular carcinoma (NBNC-HCC).
-
Intermittent fasting regimens for metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis of randomized controlled trials. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-23 Mohamed T Abuelazm, Islam Mohamed, Ahmed Naeem, Yehya Khlidj, Mohammad Tanashat, Basant E Katamesh, Husam Abusuilik, Obieda Altobaishat, Mohamed Abdelnabi, Basel Abdelazeem
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent metabolic disorder characterized by excessive hepatic fat accumulation. Intermittent fasting (IF) has emerged as a potential therapeutic strategy with the ability to induce weight loss, improve insulin sensitivity and reduce hepatic steatosis. We aim to compare the efficacy of different IF regimens for MASLD management
-
Metabolic dysfunction-associated steatotic liver disease and the risk of mortality in individuals with type 2 diabetes: a systematic review and meta-analysis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-23 Wasit Wongtrakul, Natthinee Charatcharoenwitthaya, Phunchai Charatcharoenwitthaya
The systematic review aimed to assess the risks of metabolic dysfunction-associated steatotic liver disease (MASLD) on all-cause and cause-specific mortality in patients with type 2 diabetes (T2DM). EMBASE and MEDLINE were searched from inception to June 2022 for observational studies examining the relationship between MASLD and the risk of mortality among T2DM patients. Meta-analysis was conducted
-
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-21 Geert D'Haens, Filip Baert, Silvio Danese, Taku Kobayashi, Edward V Loftus, William J Sandborn, Quentin Dornic, Dirk Lindner, Krisztina Kisfalvi, Ed G Marins, Séverine Vermeire
Vedolizumab is an anti-α4β7 integrin antibody used to treat moderate to severe ulcerative colitis (UC) and Crohn's disease (CD). This post hoc analysis of patient-reported outcomes (PROs) from the VISIBLE 1 (NCT02611830) and 2 (NCT02611817) phase 3 studies evaluated onset of treatment effect on patient-reported symptoms during 6-week vedolizumab induction.
-
The perioperative experience and needs of hepatocellular carcinoma patients in interventional therapy: a phenomenological qualitative study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-21 Ling Li, Hua-Zhen Zhang, Yan Ge, Ya-Li Rao, Ting Liu, Miao-Miao Guo, Shu-Ping Xiao
This study aims to investigate the perioperative experience and needs of patients with liver cancer for interventional therapy, in order to provide the basis for further improving a patient's medical experience and satisfaction.
-
Performance assessment of a new G12/A1 antibody-based rapid ELISA using commercially available and gluten-spiked food samples. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-21 Anil K Verma, Chiara Monachesi, Giulia N Catassi, Elisa Franceschini, Simona Gatti, Elena Lionetti, Carlo Catassi
Food products with <20 mg/kg gluten can be labeled 'gluten-free' according to international regulations. Several antibodies-based ELISAs have been develop to track gluten traces in food products. Among them, R5 and G12 antibody-based ELISAs are the frequently used methods. However, these antibodies have certain limitations. We evaluated the accuracy of G12/A1 antibody-based 'Glutentox ELISA Rapid G12'
-
Can quantitative surface antigen levels and systemic immune-inflammation index be predictive as a new indicator for the initiation of treatment in chronic hepatitis b? Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-21 Mehmet Koroglu, Muhammed Ali Ayvaz, Suat Baran Bakan, Abdullatif Sirin, Umit Akyuz
The natural history of chronic HBV infection (CHB) is generally divided into four phases: HBeAg-positive chronic HBV infection (EPCI) and -hepatitis (EPCH), HBeAg-negative chronic HBV infection (ENCI) and -hepatitis (ENCH). This study aimed to investigate changes in serum quantitative surface antigen (qHBsAg), systemic immune-inflammation index (SII) and systemic inflammatory response index (SIRI)
-
Osteonecrosis in patients with inflammatory bowel disease: a systematic review and meta-analysis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-21 Himanshu Bhayana, Tarun Kumar Sharma, Alka Sharma, Mehtab S Dhillon, Anuraag Jena, Deepak Kumar, Vishal Sharma
The relationship of inflammatory bowel disease (IBD) with osteonecrosis or avascular necrosis (AVN) is uncertain.
-
Prevalence and risk factors for cirrhotic cardiomyopathy: a prospective cross-sectional study. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-16 Huawei Xu, Yu Zhang, Yanjing Gao
This study aimed to assess cardiac structure and function in patients with cirrhosis, to investigate the prevalence of cirrhotic cardiomyopathy (CCM) in patients with cirrhosis of different etiologies and to analyze the risk factors for the development of CCM.
-
Renal dysfunction during treatment of chronic hepatitis B with tenofovir disoproxyl fumarate and associated risk factors. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-16 Alessandra M de A Maciel, Maria Lucia C G Ferraz, Renata de M Perez, Carlos Eduardo Brandão-Mello
To analyze the evolution of glomerular filtration rate (GFR) and the presence of renal tubular dysfunction during the treatment of chronic hepatitis B virus (HBV) infection with tenofovir disoproxil fumarate (TDF) and to determine the risk factors involved.
-
The role of donor sex on the post-liver transplant outcomes in patients with primary sclerosing cholangitis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-16 David Uihwan Lee, Ashton Harmacinski, Sindhura Kolachana, Aneesh Bahadur, KeeSeok Lee, Ki Jung Lee, Alex Pu, Harrison Chou, Gregory Hongyuan Fan, Raza Malik
Primary sclerosing cholangitis (PSC) can result in hepatic decompensation and require liver transplantation (LT). This study investigates the effect of the sex of the donor and recipient as a prognostic risk factor for adverse outcomes after LT in patients with PSC.
-
Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-02-16 Yaqing Bai, Yinghao Sun, Qi He, Xiaoyin Bai, Hong Yang
Ustekinumab has two alternative drug maintenance intervals for inflammatory bowel disease (IBD), every 8 weeks (Q8W) and every 12 weeks (Q12W). The current study aimed at evaluating the comparative efficacy and safety of the two maintenance intervals in patients with IBD. A systematic search on PubMed, Web of Science, Cochrane Library, and EMBASE was carried out. The relative risk (RR) was pooled for
-
Intestinal barrier biomarkers in clinical evaluation of patients with inflammatory bowel disease. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-01-31 Tamara Mogilevski, Anke L Nguyen, Mary Ajamian, Rebecca Smith, Sam Rosella, Miles P Sparrow, Gregory T Moore, Peter R Gibson
Inflammatory bowel disease (IBD) is associated with chronic intestinal barrier dysfunction, though its non-invasive assessment remains challenging. This study aimed to determine how four putative circulating markers vary across differing states of intestinal inflammation and with therapy in patients with IBD.
-
Variation in proliferative and cell cycle markers in Barrett's esophagus in relation to circumferential and axial location in the esophagus. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-01-22 Nosheen Umar, Lance Alleyne, Danny Cheung, James Rees, Caitlin Trudgill, Ulises Zanetto, Suhail Muzaffar, Nigel Trudgill
Adenocarcinoma in Barrett's esophagus (BE) occurs more frequently between 12 and 3 o'clock at the gastroesophageal junction (GEJ).
-
Unraveling the blood microbiome: novel insights into inflammasome responses in Crohn's disease. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-01-22 Duygu Kirkik, Sevgi Kalkanli Tas, Alpaslan Tanoglu
Crohn's disease (CD), an inflammatory bowel disease with unknown etiology, is influenced by genetic, environmental, and immunological factors. This study aimed to analyze the blood microbiome and inflammasome responses, emphasizing NLRP3 protein expression and IL-1β and IL-18 plasma levels, between Crohn's patients and healthy subjects.
-
Late presentation for hepatitis C treatment: prevalence and risk factors in the Swiss Hepatitis C Cohort. Eur. Gastroenterol. Hepatol. (IF 2.1) Pub Date : 2024-01-22 Nathalie Brunner, Thomas Grischott, Philip Bruggmann
Patients with 'late presentation' (LP) of chronic hepatitis C infection (HCV) have already developed advanced liver disease before receiving direct-acting antiviral (DAA) treatment. Even after successful treatment, the risk of morbidity and premature death remains elevated, leading to an unnecessary disease burden. This study aimed to assess the prevalence of LP within the prospective observational